Immunotherapy has shown limited effectiveness for most prostate cancer patients, with response rates in the single digits for the checkpoint inhibitors that have transformed treatment of other cancers. The one FDA-approved immunotherapy for prostate cancer, a personalized vaccine called sipuleucel-T (Provenge), extends survival by about four months in men with advanced disease. A small subset of patients with specific genetic features respond much better, but they represent roughly 3% of advanced cases. The picture is more nuanced than a simple yes or no, and understanding which approaches work, for whom, and why most don’t is key to setting realistic expectations.
Why Prostate Cancer Resists Immunotherapy
Prostate cancer is what researchers call an immunologically “cold” tumor. That means it has a low number of genetic mutations, limited infiltration of the immune cells that kill cancer, and an environment around the tumor that actively suppresses immune activity. In cancers like melanoma or lung cancer, high mutation rates create lots of abnormal proteins for the immune system to recognize. Prostate tumors simply don’t give the immune system much to work with.
The tissue surrounding prostate tumors is also stacked against immune attack. Regulatory T-cells, suppressive macrophages, and other immune-dampening cells congregate around the tumor and release signals that exhaust or disable the cancer-killing T-cells that do show up. Specialized stromal cells called cancer-associated fibroblasts remodel the physical structure around the tumor and recruit even more suppressive immune cells, reinforcing the “cold” environment. Even when the body sends immune cells toward the tumor, suppressive cells intercept them, starving them of nutrients and shutting them down through chemical signals. This hostile microenvironment is the central reason that therapies working well in other cancers have largely failed in prostate cancer.
Sipuleucel-T: The Only Approved Option
Sipuleucel-T remains the only immunotherapy specifically approved for prostate cancer. It’s a personalized cancer vaccine designed for men with metastatic castration-resistant prostate cancer (mCRPC) who have few or no symptoms. The treatment involves collecting a patient’s own immune cells through a blood-filtering process called leukapheresis, exposing those cells to a protein found on prostate cancer cells, and then infusing the activated cells back into the patient. This cycle repeats three times at roughly two-week intervals, with each blood collection happening about three days before the infusion.
In the landmark IMPACT trial published in the New England Journal of Medicine, sipuleucel-T improved median overall survival from 21.7 months to 25.8 months compared to placebo. At three years, 31.7% of treated patients were alive versus 23.0% in the placebo group. That 4.1-month survival benefit is real but modest, and notably, the treatment doesn’t shrink tumors or lower PSA levels in most patients. It appears to prime the immune system in a way that slows disease progression over time rather than producing visible tumor responses. Side effects are generally mild, mostly flu-like symptoms and infusion reactions. Serious immune-related side effects from cancer vaccines occur in about 2% of patients.
Checkpoint Inhibitors: Disappointing for Most
Checkpoint inhibitors, the drugs that block PD-1, PD-L1, or CTLA-4 and have revolutionized treatment of melanoma, lung cancer, and bladder cancer, perform poorly in unselected prostate cancer patients. In the KEYNOTE-199 trial, pembrolizumab given alone to men with mCRPC produced objective response rates of just 5% in patients whose tumors expressed PD-L1 and 3% in those whose tumors did not. A phase 1 study of atezolizumab in mCRPC showed a PSA response rate of only 8.6%. Nivolumab monotherapy produced zero objective responses in the prostate cancer subset of a broader trial.
The patients who did respond to single-agent checkpoint therapy tended to have durable responses, meaning the benefit lasted a long time when it occurred. But the odds of being one of those responders are very low without a specific biomarker to predict benefit.
The 3% Who Respond Well
There is a clear exception to prostate cancer’s poor immunotherapy track record. About 3.1% of men with advanced prostate cancer have tumors classified as MSI-high or mismatch repair deficient (dMMR), meaning their cancer cells have a broken DNA repair system that leads to many more mutations than typical prostate tumors. These extra mutations create the kind of abnormal proteins that make a tumor visible to the immune system.
In the KEYNOTE-158 trial, pembrolizumab produced an objective response rate of 34.3% across MSI-high cancers from multiple organ sites. For prostate cancer patients specifically with dMMR tumors treated with anti-PD-1 therapy, PSA response rates reached 65% with a median progression-free survival of about six months. That’s a dramatic contrast to the 3-5% response rates seen in unselected patients. Genomic testing of tumor tissue can identify these patients, and guidelines now recommend testing for mismatch repair deficiency in advanced prostate cancer to identify the small group who may benefit substantially from checkpoint inhibitors.
Combination Approaches Show Promise in Selected Patients
Combining two checkpoint inhibitors, one targeting PD-1 and one targeting CTLA-4, has shown better activity than either alone, particularly in patients whose tumors carry specific immune-related features. The phase II NEPTUNES study tested nivolumab plus ipilimumab in men with mCRPC whose tumors had an “immunogenic signature,” meaning genetic features suggesting the cancer might respond to immune-based treatment.
The composite response rate was 32% across all patients in the trial. Responses varied sharply by tumor genetics. Patients with mismatch repair deficiency responded at the highest rate (7 out of 10), and those with BRCA2 loss responded half the time (4 out of 8). The duration of response also varied: patients with DNA repair gene loss maintained responses for a median of over 17 months, while those selected only by high immune infiltration saw responses lasting a median of 2.6 months. The higher-dose ipilimumab combination was more active but also more toxic. Serious immune-related side effects occur in about 15% of patients receiving ipilimumab-based combinations, compared to 5-6% with PD-1 inhibitors alone. These side effects can include inflammation of the colon, liver, lungs, or skin.
Experimental Approaches: CAR-T Cells
CAR-T cell therapy, which has been highly effective in certain blood cancers, is being tested in prostate cancer by engineering a patient’s T-cells to recognize PSMA, a protein abundant on prostate cancer cells. A first-in-human phase 1 trial tested CAR-T cells that were also engineered to resist one of the suppressive signals in the prostate tumor microenvironment.
Of 13 patients who received the therapy, 4 (about 30%) had PSA declines of at least 30%. One patient achieved a near-complete PSA response, dropping to undetectable levels within two weeks, though this patient died from severe cytokine release syndrome complicated by infection. No patients achieved a formal partial response by standard imaging criteria, though 5 of 13 (38.5%) maintained stable disease at three months. Median overall survival was about 16 months, and median progression-free survival was 4.4 months. Notably, researchers observed that after the CAR-T cells entered the tumor, the tumor microenvironment rapidly upregulated multiple inhibitory molecules, essentially finding new ways to shut down the engineered cells. This underscores the challenge of overcoming prostate cancer’s immunosuppressive defenses even with highly targeted cell therapies.
What This Means in Practical Terms
For the average man with advanced prostate cancer, immunotherapy currently offers a modest survival benefit through sipuleucel-T and very low odds of response from checkpoint inhibitors. The most important step is getting your tumor tested for mismatch repair deficiency or MSI-high status, because the small fraction of patients with these features have response rates that rival what’s seen in more immunotherapy-responsive cancers. If your tumor carries these markers, or other features like BRCA2 loss, combination checkpoint therapy becomes a much more reasonable option.
For the remaining majority, hormonal therapies, chemotherapy, and targeted treatments like PARP inhibitors or radioligand therapy currently provide more reliable benefit. Immunotherapy for prostate cancer is not a dead end, but it is a field where patient selection matters enormously, and blanket treatment of all comers has consistently produced disappointing results.